A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas

ClinicalTrials.gov ID: NCT01118377

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01118377. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study evaluated the effect of capecitabine and concomitant radiation therapy in children with newly diagnosed brainstem gliomas.

Study identification

NCT ID: NCT01118377
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 45 participants

Conditions and interventions

Conditions

Brainstem Glioma

Interventions

Capecitabine Drug
Radiation therapy Radiation

Drug · Radiation

Eligibility (public fields only)

Age range: 3 Years to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2007 (Type not available)
Primary completion: Jan 2013 (Actual)
Completion: Apr 2013 (Actual)
Last update posted: Feb 6, 2014

2007 – 2013

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
Not listed	San Francisco	California	94143-0780	—
Not listed	Washington D.C.	District of Columbia	20010	—
Not listed	Chicago	Illinois	60614	—
Not listed	Durham	North Carolina	27710	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Pittsburgh	Pennsylvania	15261	—
Not listed	Memphis	Tennessee	38015	—
Not listed	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01118377, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 6, 2014 · Synced Nov 12, 2026